Amniotics™, formerly Longboat Amniotics, was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue relevant neonatal quality mesenchymal stem cells (MSCs). Researchers and founders of the company, pediatrician Marcus Larsson, obstetrician Andreas Herbst and stem cell specialist Niels-Bjarne Woods discovered a new type of stem cells in amniotic fluid that has unique properties for applications in regenerative medicine.
In the summer of 2019, the company raised 20 MSEK for the validation of our MSCs in preclinical models for lung disease as well as for the completion and process validation of the GMP manufacturing facility. With the new GMP facilities operational in early 2020, Amniotics™ is now looking to establish strategic partnerships with companies that are interested in developing stem-cell-based therapies targeting diseases with unmet needs.
To contribute to the successful treatment of human diseases by providing the very best stem cell for medical applications. We are devoted to developing innovative life-changing and regenerative treatments for patients.
Deliver safe and effective innovative therapies to patients with unmet medical needs.
The strategy is to develop treatments for diseases with severe inflammatory and fibrotic components, where tissue-relevant stem cells can be expected to have an impact and be life-changing treatments.
The objective is to successfully conduct and complete planned clinical trials with our tissue-relevant MSCs.
Amniotics™ is presently producing technical batches of our lung-appropriate cells and qualifying the premises for ATMP production and GMP inspection. With the results from our preclinical studies and the characterization of the quality attributes of the cells (sterility, stability, identity, purity, potency, injectability), we are moving towards clinical trials with speed, with a focus set for treatment of COVID-19.
At Amniotics™, we aim to positively impact the lives of patients and their families with severe diseases by developing innovative therapies. With our novel treatments in development, we strive to help as many patients as possible as fast as possible.
CEO since 2019
COO since 2017
Head of Business Development since 2020
Director Clinical & Regulatory Affairs since 2020
Jonas Lundahl holds a PhD from the Faculty of Medicine at the University of Gothenburg and a Master’s degree in Pharmaceutical Business Strategy from Copenhagen Business School. Jonas Lundahl has over 30 years of international experience in leading positions in R& D at ma-jor pharmaceutical companies. Jonas Lundahl has previously worked at Astra Zeneca, Ferring Pharmaceutical, Lundbeck and LEO Pharma, whereby he has gained extensive experience in the management of clinical and regulatory strategy for international drug development. Jonas Lundahl’s field of activity has included more than 10 global development programs in psychia-try, neurology, urology, immunology and dermatological diseases. Prior to joining Amniotics, Jonas Lundahl was senior medical science lead at LEO Pharma for three years.
Other ongoing assignments: Holder of Lundahl’s pharmaceutical consultancy.
Peter Buhl Jensen
Chairman of the Board since 2021
Peter Buhl Jensen is MD specialist in internal medicine and has a DMSc. Peter Buhl Jensen has a strong combination of commercial experience and medical expertise, especially in oncology, and has written over 120 scientific articles. Peter Buhl Jensen is the founder of TopoTarget A/S, Allarity Therapeutics (formerly Oncology Venture) and Medical Prognosis Institute A/S, as well as several successful ventures in the Life Science sector. Peter Buhl Jensen backed TopoTarget’s IPO in 2005 and secured EMA and FDA approval of the company’s first product, Savene©/Totect©. Peter Buhl Jensen was also involved in the IPO of Allarity Therapeutics and the Medical Prognosis Institute. In addition, Peter Buhl Jensen is behind the development of the drug Belinostat, which was approved by the FDA in the summer of 2014. Peter Buhl Jensen has leadership experience from TopoTarget, where he led approximately 140 employees, as well as from Aalborg University Hospital where he was a senior consultant at the Department of Oncology and led approximately 280 employees. Furthermore, Peter Buhl Jensen is an adjunct professor of clinical oncology at the University of Copenhagen and has been a consultant physician and led LEMO (Laboratory of Experimental Medical Oncology) at Rigshospitalet University Hospital in Copenhagen.
Other ongoing assignments: Board member of Cobis A/S, Symbion A/S and Symbion Foundation. CEO of Symbion A/S. Member of the Management Board (Executive Board) of Buhl Krone Holding ApS.
Board member since 2017
Anders Månsson holds a bachelor’s degree in business and economics from Lund University and an MBA from Business School Lausanne. Anders Månsson has more than 25 years of experience in the pharmaceutical industry and life sciences, as well as experience from several leading positions within multinational pharmaceutical companies both in Sweden and abroad, primarily in sales, marketing and business development, which included work on distribution and licensing agreements, divestments and acquisitions in the billion class. In recent years, Anders Månsson was the previous CEO of Amniotics AB, he has been Industrial Advisor in Life Science to Ratos AB and Vice President of LEO Pharma. Anders Månsson is currently CEO of RhoVac AB, a biotechnology company active in immuno-oncology.
Other ongoing assignments: Chairman of the Board of EQL Pharma AB. Board member and CEO of Anders Månsson Business Development AB. CEO of RhoVac AB and RhoVac ApS.
Founding member. Board member since 2015, former Chairman of the Board
Christer Fåhraeus holds a master’s degree in medical physics, a PhD in neurophysiology, a bachelor’s degree in medicine, a bachelor’s degree in mathematics and an honorary doctorate in technology from Lund University. Christer Fåhraeus has many years of board and chairman experience from listed and unlisted companies in the Life Science and tech sector, and is the founder of Agellis Group AB, Anoto Group AB, Precise Biometrics AB, CellaVision AB, EQL Pharma AB and FlatFrog Laboratories AB.
Other ongoing assignments: Chairman of the Board of ApoEco Sverige AB, BionamicAB, Bizz Bike Sweden AB, Respiratorius AB (publ) and Uman Sense AB. Board member of CellaVision AB, EQL Pharma AB, Eql Pharma Int AB, FlatFrog Laboratories AB, Fåhraeus Institute AB,Fårö Capital AB, Gasporox AB (publ), IntuiCell AB, Reccan Diagnostics AB, ScandiDos AB, Serstech AB, Serstech Förvaltning AB, Smältan Invest AB, Theope Seed Capital AB and Wranne Fåhraeus Design AB. Deputy Board member of Bergdalsten Kemi AB and CJ Scandinavian Seaview Consulting AB. CEO of EQL Pharma AB.
Board member since 2021
Christopher Bravery holds a PhD in immunology from Imperial College, London, and a bachelor’s degree in biochemistry. Christopher Bravery is a researcher with over 20 years of experience in the pharmaceutical industry and with a primary focus on advanced therapies including Advanced Therapy Medicinal Products (ATMP),cells, gene and tissue products and other products for regenerative medicine. Christopher Bravery has deep knowledge of preclinical regulatory science from work in both the biotechnology industry and work at the regulatory authority. Christopher Bravery also has a good understanding of clinical trials in the EU, as well as licensing and post-licensing requirements from experience as a reviewer at the Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency. During his time at the MHRA, Christopher Bravery was involved in the national implementation of the Regulation of the European Parliament and of the Council on advanced therapy medicinal products and has also been active on the European Medicines Agency’s Committee on Medicinal Products for Human Use’s Working Group on Cell Products.
Other ongoing assignments: CEO of Consulting on Advanced Biologicals Ltd.
Board member since 2021
Fredrik Tiberg holds a MSc in Chemical Engineering from Lund University of Technology and a PhD in Physical Chemistry at Lund University. Fredrik Tiberg has extensive experience from the biotechnology and pharmaceutical industry. He has since 2003 served as President & CEO, Head of R&D at Camurus AB, where he is also a member of the board. Previous roles include CEO of Heptahelix AB, adjunct professor of surface chemistry at Lund University and visiting professor of physical and theoretical chemistry at the University of Oxford.
Fredrik has more than 110 publications in peer-reviewed scientific journals, is named inventor on more than 400 patents and patent applications and is a member of the Royal Swedish Academy of Engineering Sciences (IVA).
Other ongoing assignments: Board member of Camurus AB, Camurus Development AB, and Camurus Lipid Research Foundation. President and CEO of Camurus AB.
Ingrid Atteryd Heiman
Board member since 2021
Ingrid Atteryd Heiman holds a BA in financing and industrial marketing from Lund University and an MBA in International Business from Uppsala University. She has more than 15 years of experience in the self-care market as CEO and Chairman of the trade association, Svensk Egenvård and its European counterpart as well as CEO and Chairman of the Board of Ellen AB. Ingrid Atteryd Heiman also has experience in management and board work with a focus on food, pharmaceuticals, biomedicine, Life Science and women’s health as well as experience as a board member and chairman of the board from several listed Life Science companies. Ingrid Atteryd Heiman has successfully proven her ability to strategize business development and drive profit and growth, and through her experience in management consulting in Booz (now part of PwC), has been involved in efficiency optimization, strategy development, mergers and acquisitions and IPOs. In addition, ms. Atteryd Heiman has experience in international business including business development in Europe, US and Asia, as well as work with lobbying in the European Parliament.
Other ongoing assignments: Chairman of the Board of Doxa AB and Doxa Dental AB. Board member of Dignitana AB (publ), Pharmiva AB (publ), Redwood Pharma AB (publ), CarpoNovum AB, and Ilama AB.
Board member since 2019
Lars Stigsson has a master’s degree from Lund Institue of Technology, and is a recognized inventor and entrepreneur with a long experience from innovation linked primarily to the forest and chemical industries. Lars Stigsson’s experiences include the founding of HydrogenHorizon AB, SunPine, SunCarbon, ShareTex and TreeToTextile AB. Furthermore, Lars Stigsson has broad experience in translating innovations into concrete business and industrial production. Lars Stigsson is the inventor of over 20 patent series related to biofuels, innovative textile fiber processes and biorefinery technology in the forest industry. Lars Stigsson was awarded the Polhem Prize in 2018 for his work on climate positive processes.
Other ongoing assignments: Chairman of the Board of LSCS Invest AB, HydrogenHorizon AB, ShareTex AB and Kiram Aktiebolag. Board member of TreeToTextile AB, Polynex Technologies AB, SunCarbon AB and BioShare AB.
Founding member. Board member since 2015
Marcus Larsson is a licensed physician with a degree from Lund University and a specialist in pediatrics and clinical practice at neonatal clinic, Skåne University Hospital. Marcus Larsson has a PhD in clinical physiology with a special focus on the surface structure and function of the lung and is one of the founders of Amniotics. Marcus Larsson has over 20 years of research experience in physiology and biophysical chemistry and is co-inventing several patents in the field of pharmaceuticals and biotechnology. Marcus Larsson is also Chairman of the Board of Camurus Lipid Research Foundation.
Other ongoing assignments: Board member of Deflexum AB.